Published in J Pathol on January 01, 1999
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol (2004) 1.72
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol (2004) 1.18
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer (2003) 0.96
Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. J Clin Pathol (2001) 0.90
The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Breast Cancer Res (1999) 0.85
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res (2005) 0.84
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol (2010) 0.83
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res (2013) 0.82
High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. J Pathol Clin Res (2016) 0.79
Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers. J Cancer Res Clin Oncol (2004) 0.79
Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast. Oncol Lett (2014) 0.79
Relation between the rate of tumour cell proliferation and latency time in radiation associated breast cancer. BMC Cancer (2003) 0.78
Factors that influence the incidence of breast cancer in Arica, Chile (Review). Oncol Lett (2010) 0.76
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Growth and transplantation of a custom vascularised bone graft in a man. Lancet (2004) 3.01
Effect of pregnancy on prognosis for young women with breast cancer. Lancet (1994) 2.92
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst (2001) 2.74
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst (2000) 2.41
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
Indicators of prognosis in node-negative breast cancer. N Engl J Med (1990) 2.23
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet (2001) 2.19
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Is the use of sunscreens a risk factor for malignant melanoma? Melanoma Res (1995) 2.11
Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int (2007) 2.08
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer (1998) 2.06
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Ann Oncol (2012) 2.02
Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution. Eur J Surg Oncol (2013) 1.99
Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem (1998) 1.94
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis (1997) 1.79
Familial testicular cancer in Norway and southern Sweden. Br J Cancer (1996) 1.76
Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol (1994) 1.74
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72
Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer (1992) 1.71
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging (2000) 1.71
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br J Cancer (2000) 1.67
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia (2004) 1.64
Occupational handling of chemicals preceding Hodgkin's disease in men. Br Med J (1979) 1.56
Increased cancer risk in offspring of women with colorectal carcinoma: a Swedish register-based cohort study. Cancer (2000) 1.52
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry (2001) 1.49
Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort. J Intern Med (2014) 1.47
Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study. Br J Dermatol (2004) 1.46
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer (1992) 1.46
Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol (1998) 1.44
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res (1998) 1.37
Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci U S A (2000) 1.36
Oral contraceptive use and breast cancer in young women in Sweden. Lancet (1985) 1.36
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer (1992) 1.34
Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay. Nucleic Acids Res (1997) 1.32
Histochemical studies on the metabolism of L-DOPA and some related substances in the exocrine pancreas. Acta Physiol Scand (1969) 1.32
Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum Pathol (1998) 1.31
A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer (1997) 1.31
Peptidergic (substance P) nerves in the genito-urinary tract. Neuroscience (1978) 1.31
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer (2001) 1.31
Myofibromatosis-like hemangiopericytoma metastasizing as differentiated vascular smooth-muscle and myosarcoma. Myopericytes as a subset of "myofibroblasts". Am J Surg Pathol (1992) 1.30
Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer (2000) 1.30
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood (1997) 1.29
ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene (1991) 1.27
[Drug-induced esophageal strictures]. Lakartidningen (1978) 1.27
The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res (1992) 1.27
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer (2004) 1.26
KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol (1992) 1.23
Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr (2003) 1.23
HER2/neu amplification and comedo type breast carcinoma. Lancet (1989) 1.22
Reproducibility of a self-administered questionnaire for assessment of melanoma risk. Int J Epidemiol (1996) 1.22
Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clin Exp Immunol (1998) 1.21
Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer (1992) 1.20
Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer (1991) 1.20
Telomeres, telomerase and cancer: an up-date. Virchows Arch (2000) 1.18
Size-selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of shunt pathways. Kidney Int (1998) 1.18
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer (1999) 1.17
Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer (1990) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Naive empiricism and dogmatism in confidence research: a critical examination of the hard-easy effect. Psychol Rev (2000) 1.14
Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol (1998) 1.12
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett (1994) 1.11
Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol (2001) 1.11
NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol (1999) 1.10
Protein gene product 9.5 (PGP 9.5). A new neuronal marker visualizing the whole uterine innervation and pregnancy-induced and developmental changes in the guinea pig. Histochemistry (1988) 1.10
Distribution, origin and projections of nitric oxide synthase-containing neurons in gut and pancreas. Neuroscience (1994) 1.09
Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry (1984) 1.09